<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>Alfresa Holdings Corporation — News on 6ix</title>
<link>https://6ix.com/company/alfresa-holdings-corporation</link>
<description>Latest news and press releases for Alfresa Holdings Corporation on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Fri, 19 Sep 2025 12:00:00 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/alfresa-holdings-corporation" rel="self" type="application/rss+xml" />
<image>
<url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo69d615c0beedb30cb6fbd4ea.webp</url>
<title>Alfresa Holdings Corporation</title>
<link>https://6ix.com/company/alfresa-holdings-corporation</link>
</image>
<item>
<title>neffy® (epinephrine nasal spray) Approved in Japan as the First and Only Needle-Free Emergency Treatment of Allergic Reactions (anaphylaxis)</title>
<link>https://6ix.com/company/alfresa-holdings-corporation/news/neffyr-epinephrine-nasal-spray-approved-in-japan-as-the-first-and-only-needle-free-emergency-treatment-of-allergic-reactions-anaphylaxis</link>
<guid isPermaLink="true">https://6ix.com/company/alfresa-holdings-corporation/news/neffyr-epinephrine-nasal-spray-approved-in-japan-as-the-first-and-only-needle-free-emergency-treatment-of-allergic-reactions-anaphylaxis</guid>
<pubDate>Fri, 19 Sep 2025 12:00:00 GMT</pubDate>
<description>neffy 1 mg and 2 mg doses approved by Japanese regulators neffy offers a new delivery method for epinephrine in Japan for adults and children (>15 kg) living with severe allergic reactions Alfresa Holdings, which owns the rights to market neffy in Japan, expects availability in Q4 2025 SAN DIEGO, Sept. 19, 2025 (GLOBE NEWSWIRE) -- ARS Pharmaceuticals, Inc. (Nasdaq: SPRY), a biopharmaceutical company dedicated to empowering at-risk patients and their caregivers to better protect themselves from a</description>
</item>
</channel>
</rss>